110
Participants
Start Date
October 23, 2020
Primary Completion Date
June 1, 2025
Study Completion Date
September 1, 2035
CT041
treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
The Mount Sinai Hospital, New York
Memorial Sloan Kettering Cancer Center, New York
Northwell Cancer Institute, New Hyde Park
Moffitt Cancer Center, Tampa
Ohio State University, Columbus
Karmanos Cancer Center, Detroit
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Mayo Cancer Hospital, Rochester
University of Kansas Cancer Center, Kansas City
TX Oncology-Baylor Charles Sammons Cancer Center, Dallas
MD Anderson Cancer Center, Houston
University of Southern California, Los Angeles
City of Hope, Duarte
UCSD, San Diego
UCSF, San Francisco
Princess Margaret Hospital, Toronto
Lead Sponsor
CARsgen Therapeutics Co., Ltd.
INDUSTRY